Pharming Group N.V. offers to acquire Abliva AB to strengthen pipeline with KL1333

From GlobeNewswire: 2024-12-15 13:45:00

Pharming Group N.V. announced a recommended public cash offer to acquire Abliva AB, strengthening its late-stage pipeline with the potential first-in-disease treatment KL1333. The total transaction value is approximately US$66.1 million, with no external funding required. Abliva’s lead product, KL1333, has shown positive interim analysis results in a pivotal clinical trial for primary mitochondrial diseases, offering hope to over 30,000 potential patients. Pharming plans to host a conference call on December 16, 2024, to discuss the acquisition and development of KL1333, which is expected to launch in the U.S. by 2028.



Read more at GlobeNewswire: Pharming announces public cash offer to the shareholders of